What question did this study set out to answer?

To investigate the efficacy and safety of sequential ethylmethylhydroxypyridine succinate therapy as an adjunct to comprehensive rehabilitation for improving emotional, cognitive, and motor outcomes in acute cerebral insufficiency.

December 5, 2024Physical and rehabilitation medicine medical rehabilitationOpen Access

Dynamics of emotional-cognitive and motor disorder domains in the Post Intensive Care Syndrome structure in acute cerebral insufficiency patients

View Full Paper

Ask AI

Bookmark

Authors

АБА. А. БелкинClinical Institute of Brain VBVladimir A. BelkinClinical Institute of Brain IVIgor E. VasilchenkoClinical Institute of Brain

Discussion

Member takes

Implication

Randomized trial demonstrates ethylmethylhydroxypyridine succinate improves anxiety, mobility, and disability in acute cerebral insufficiency, suggesting enhanced post-intensive care recovery.

Key Points

To investigate the efficacy and safety of sequential ethylmethylhydroxypyridine succinate therapy as an adjunct to comprehensive rehabilitation for improving emotional, cognitive, and motor outcomes in acute cerebral insufficiency.
Randomized, prospective interventional study involving N=60 patients with acute cerebral insufficiency evaluated across five clinical visits.
The intervention group received standard therapy plus ethylmethylhydroxypyridine succinate (500 mg/day IV for 10 days) followed by an oral formulation (FORTE 250, 1 tablet 3 times/day for 8 weeks); the control group received standard therapy alone.
Anxiety on the HADS scale was significantly reduced at visit 4 in the intervention group compared with control (median 2 [1; 4] vs 5 [2.25; 7], p < 0.01), whereas MoCA score improvements were comparable across both cohorts (p < 0.001).
The intervention group achieved higher Rivermead Mobility Index scores at visit 5 (median difference of 3 points over control, p < 0.001) and had a significantly lower proportion of disabled patients with a Rehabilitation Routing Scale score ≥3 (Yates χ² = 4, p = 0.045).
PICS incidence exhibited a downward trend in the intervention arm between visits 3 and 5 compared to control (Yates χ² = 3.491, p = 0.062), with zero adverse events recorded during the trial.

Cite This Study

Белкин et al. (2024) studied this question.

synapsesocial.com/papers/69f849382edb3aad51a62ddf https://doi.org/10.36425/rehab635419

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates ethylmethylhydroxypyridine succinate improves anxiety, mobility, and disability in acute cerebral insufficiency, suggesting enhanced post-intensive care recovery.

Dynamics of emotional-cognitive and motor disorder domains in the Post Intensive Care Syndrome structure in acute cerebral insufficiency patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Dynamics of emotional-cognitive and motor disorder domains in the Post Intensive Care Syndrome structure in acute cerebral insufficiency patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider